• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session

    12/11/23 1:12:59 PM ET
    $APLS
    $BLUE
    $BMEA
    $BPMC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $APLS alert in real time by email

    Shares of bluebird bio, Inc. (NASDAQ:BLUE) rose sharply during Monday’s session after the company presented updated data from its gene therapy program in transfusion-dependent beta-thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition.

    bluebird bio shares rose 6.6% to $3.05 on Monday.

    Here are some other stocks moving in today's mid-day session.

    Gainers

    • Pasithea Therapeutics Corp. (NASDAQ:KTTA) shares jumped 142.6% to $0.7399 after the company announced preclinical results from two in vivo studies evaluating the antitumor efficacy of PAS-004 in NRAS mutation cancer xenograft models.
    • NextPlay Technologies, Inc. (NASDAQ:NXTP) shares climbed 79.4% to $0.7538 on continued volatility after the company last week received notification for not meeting the deadline to file its financial reports for several periods in 2023.
    • Jet.AI Inc. (NASDAQ:JTAI) climbed 66% to $2.7550. The company recently posted a narrower quarterly loss.
    • Assure Holdings Corp. (NASDAQ:IONM) gained 69.9% to $0.5950.
    • Intchains Group Limited (NASDAQ:ICG) rose 25.8% to $11.02.
    • Professional Diversity Network, Inc. (NASDAQ:IPDN) rose 23.3% to $2.64.
    • Minim, Inc. (NASDAQ:MINM) gained 20% to $3.7450.
    • MorphoSys AG (NASDAQ:MOR) rose 17.4% to $8.28 as the company presented comprehensive results from the Phase 3 MANIFEST-2 study investigating pelabresib at 65th American Society of Hematology Annual Meeting.
    • The Cigna Group (NYSE:CI) shares gained 16.8% to $302.25. Cigna has withdrawn from its proposed merger with
    • Humana Inc. (NYSE:HUM).
    • Macy's, Inc. (NYSE:M) rose 16.4% to $20.24. An investor consortium has tabled a $5.8 billion bid to acquire Macy's, in an attempt to privatize the iconic department store chain.
    • Onconova Therapeutics, Inc. (NASDAQ:ONTX) shares rose 15.6% to $0.7421. Onconova Therapeutics' preclinical narazaciclib data at SABCS highlighted differentiated anti-tumor activity v. other CDK4/6i's.
    • Dogness (International) Corporation (NASDAQ:DOGZ) gained 14.7% to $3.50.
    • Conduit Pharmaceuticals Inc. (NASDAQ:CDT) rose 14% to $5.87.
    • Inhibikase Therapeutics, Inc. (NASDAQ:IKT) climbed 13.8% to $1.40.
    • CommScope Holding Company, Inc. (NASDAQ:COMM) gained 13% to $2.0785. CommScope Holding SVP & President, CCS Koen Linde Ter acquired a total of 13,513 shares at an average price of $1.84.
    • Blueprint Medicines Corporation (NASDAQ:BPMC) rose 8.2% to $80.07. Blueprint Medicines announced data showcasing its commitment to advance the scientific understanding and treatment of systemic mastocytosis was highlighted at 2023 ASH Annual Meeting.
    • Shake Shack Inc. (NYSE:SHAK) gained 8.3% to $66.02. CEO Randy Garutti will retire from Shake Shack in 2024. The company also reiterated its fourth quarter and FY23 guidance.

    Losers

    • Near Intelligence, Inc. (NASDAQ:NIR) fell 44.4% to $0.0845. Near Intelligence filed for Chapter 11 protection and entered into agreement to sell its business.
    • African Agriculture Holdings Inc. (NASDAQ:AAGR) fell 41.6% to $1.34 after dipping 49% on Friday.
    • Altamira Therapeutics Ltd. (NASDAQ:CYTO) fell 40.7% to $0.2430 after the company issued investor and business update. The company's board has decided to effect a 20-for-1 reverse stock split on Dec. 13, 2023.
    • Green Giant Inc. (NASDAQ:GGE) fell 40% to $0.1522 after announcing a proposed public offering.
    • Biomea Fusion, Inc. (NASDAQ:BMEA) shares fell 32.2% to $11.40 after the company announced it presented data for BMF-219 in relapsed / refractory AML patients with menin-dependent mutations at the ASH 2023 Annual Meeting.
    • Troika Media Group, Inc. (NASDAQ:TRKA) declined 30% to $0.2344. Troika Media Group recently announced it filed for Chapter 11.
    • Veru Inc. (NASDAQ:VERU) fell 29.1% to $0.83.
    • X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) fell 25.6% to $0.6531. X4 Pharmaceuticals announced presentation of additional data from mavorixafor Phase 2 trial in chronic neutropenia at ASH 2023.
    • Cyngn Inc. (NASDAQ:CYN) fell 24.5% to $0.1594. Cyngn shares fell 47% on Friday after the company announced pricing of a $5 million public offering of common stock.
    • RiskOn International, Inc. (NASDAQ:ROI) shares fell 22.9% to $0.1460. RiskOn International recently said Kurt Flygare has been appointed Chief Executive Officer of GuyCare Management, Inc., a subsidiary of GuyCare, Inc.
    • Kodiak Sciences Inc. (NASDAQ:KOD) fell 22.4% to $2.4501. Goldman Sachs reinstated Kodiak Sciences with a Sell and announced a $2 price target.
    • Vapotherm, Inc. (NYSE:VAPO) dipped 22.3% to $1.53. Vapotherm revealed notification to NYSE of intention to voluntarily delist common stock application pending to transfer shares to OTCQX.
    • eFFECTOR Therapeutics, Inc. (NASDAQ:EFTR) fell 17.1% to $0.4293. eFFECTOR Therapeutics, on Friday, announced new interim data from dose escalation and Phase 2 expansion cohorts of a Phase 1/2 study of zotatifin in patients with estrogen receptor positive (ER+) metastatic breast cancer.
    • Keros Therapeutics, Inc. (NASDAQ:KROS) declined 16% to $29.92. Keros Therapeutics showcased Phase 2 trials on blood disorders at ASH 2023.
    • TeraWulf Inc. (NASDAQ:WULF) fell 15% to $1.5501.
    • CleanSpark, Inc. (NASDAQ:CLSK) fell 12.9% to $9.00.
    • Gildan Activewear Inc. (NYSE:GIL) declined 12.8% to $31.85. Gildan Activewear said Glenn J. Chamandy has left his position as President, CEO and Director.
    • iSun, Inc. (NASDAQ:ISUN) shares fell 10.8% to $0.1712 after declining around 7% on Friday.
    • HIVE Digital Technologies Ltd. (NASDAQ:HIVE) declined 10.6% to $3.7550 amid a pullback in the price of Bitcoin.
    • Bit Digital, Inc. (NASDAQ:BTBT) fell 10.6% to $3.1850 amid a pullback in the price of Bitcoin.
    • Riot Platforms, Inc. (NASDAQ:RIOT) dipped 10.5% to $14.16 amid a pullback in the price of Bitcoin.
    • Marathon Digital Holdings, Inc. (NASDAQ:MARA) fell 9.9% to $15.12 amid a pullback in the price of Bitcoin.
    • Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) dipped 9.2% to $56.96. Apellis said EMPAVELI (Pegcetacoplan) provided long-term control of PNH in new data presented at ASH Annual Meeting.
    • Zai Lab Limited (NASDAQ:ZLAB) fell 6.8% to $25.40.
    • DISH Network Corporation (NASDAQ:DISH) declined 5.4% to $4.3250.

     

    Now Read This: How To Earn $500 A Month From Vail Resorts Stock After Q1 Earnings Report

    Get the next $APLS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APLS
    $BLUE
    $BMEA
    $BPMC

    CompanyDatePrice TargetRatingAnalyst
    Macy's Inc
    $M
    3/19/2026$25.00 → $20.00Market Perform
    Telsey Advisory Group
    Apellis Pharmaceuticals Inc.
    $APLS
    3/13/2026$31.00Buy
    Roth Capital
    The Cigna Group
    $CI
    3/12/2026$358.00Mkt Perform → Outperform
    Bernstein
    X4 Pharmaceuticals Inc.
    $XFOR
    3/9/2026$12.00Buy
    Guggenheim
    Shake Shack Inc.
    $SHAK
    3/9/2026$118.00Outperform
    Wolfe Research
    Shake Shack Inc.
    $SHAK
    3/6/2026$125.00Buy
    DA Davidson
    Inhibikase Therapeutics Inc.
    $IKT
    3/4/2026$4.00Buy
    Ladenburg Thalmann
    MARA Holdings Inc.
    $MARA
    2/27/2026Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $APLS
    $BLUE
    $BMEA
    $BPMC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XOLREMDI issued to X4 PHARMACEUTICALS INC

    Submission status for X4 PHARMACEUTICALS INC's drug XOLREMDI (ORIG-1) with active ingredient MAVORIXAFOR has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218709, Application Classification: Type 1 - New Molecular Entity

    4/29/24 2:36:51 PM ET
    $XFOR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 17, 2022 - FDA Approves First Cell-Based Gene Therapy to Treat Adult and Pediatric Patients with Beta-thalassemia Who Require Regular Blood Transfusions

    For Immediate Release: August 17, 2022 Today, the U.S. Food and Drug Administration approved Zynteglo (betibeglogene autotemcel), the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.  “Today’s approval is an important advance in the treatment of beta-thalassemia, particularly in individuals who require ongoing

    8/17/22 2:12:27 PM ET
    $BLUE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APLS
    $BLUE
    $BMEA
    $BPMC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Thiel Frederick G

    4 - MARA Holdings, Inc. (0001507605) (Issuer)

    3/19/26 7:00:03 PM ET
    $MARA
    EDP Services
    Technology

    SEC Form 4 filed by Khan Salman Hassan

    4 - MARA Holdings, Inc. (0001507605) (Issuer)

    3/19/26 7:00:02 PM ET
    $MARA
    EDP Services
    Technology

    SEC Form 4 filed by Perlroth Victor

    4 - Kodiak Sciences Inc. (0001468748) (Issuer)

    3/19/26 5:07:32 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $APLS
    $BLUE
    $BMEA
    $BPMC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth

    NAPLES, Fla. and CAMBRIDGE, United Kingdom, March 18, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") today announced that all proposals put forth at the Special Meeting of Stockholders of CDT, held on Tuesday, March 17, 2026, were duly passed by the stockholders. "Following the successful passing of all the proposals at yesterday's Special Meeting, CDT Equity continues to transform through its $123M investment in Sarborg, the continued expansion of its IP portfolio, potential access to significant new capital and a carefully controlled annual overhead of less than $8 million," said Dr. Andrew Regan, Chief Executive Officer. "Utilizing cutting edge AI and an

    3/18/26 8:30:00 AM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gildan Announces Participation at CIBC's 29th Annual Retail and Consumer Conference in Toronto

    MONTREAL, March 18, 2026 (GLOBE NEWSWIRE) -- Gildan Activewear Inc. (GIL: TSX and NYSE) announced today that Glenn J. Chamandy, President & Chief Executive Officer, Luca Barile, Executive Vice-President, Chief Financial Officer and Jessy Hayem, Senior Vice-President, Head of Investor Relations and Global Communications will participate in a fireside chat and one-on-one meetings with investors at the 29th Annual CIBC Retail and Consumer Conference in Toronto on Wednesday, March 25, 2026. About GildanGildan is a leading manufacturer of everyday basic apparel. The Company's product offering includes activewear, underwear, socks, and intimates sold to a broad range of customers, including who

    3/18/26 8:00:00 AM ET
    $GIL
    Apparel
    Consumer Discretionary

    Macy's, Inc. and Macy's Return to Annual Comparable Sales Growth; Fourth Quarter and Fiscal Year 2025 Results Exceed Guidance

    Bold New Chapter gained traction across all nameplates during fourth quarter, driven by go-forward stores and digital Bloomingdale's achieved its best holiday performance on record in the fourth quarter Macy's expands strategic initiatives to 75 additional stores, creating "Reimagine 200" for 2026 Macy's, Inc. (NYSE:M) today reported financial results for the fourth quarter and fiscal year 2025 and provided fiscal year 2026 guidance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318878750/en/ Fourth Quarter 2025 Highlights Macy's, Inc. net sales of $7.6 billion exceeded guidance. Macy's, Inc. comparable sales1 gr

    3/18/26 6:55:00 AM ET
    $M
    Department/Specialty Retail Stores
    Consumer Discretionary

    $APLS
    $BLUE
    $BMEA
    $BPMC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bucella Michael C. bought $19,950 worth of shares (1,338 units at $14.91), increasing direct ownership by 0.49% to 273,552 units (SEC Form 4)

    4 - TERAWULF INC. (0001083301) (Issuer)

    3/13/26 5:49:13 PM ET
    $WULF
    EDP Services
    Technology

    Director Bucella Michael C. bought $30,071 worth of shares (2,085 units at $14.42), increasing direct ownership by 0.77% to 272,214 units (SEC Form 4)

    4 - TERAWULF INC. (0001083301) (Issuer)

    3/9/26 7:31:19 PM ET
    $WULF
    EDP Services
    Technology

    Director Bucella Michael C. bought $50,038 worth of shares (3,171 units at $15.78), increasing direct ownership by 1% to 270,129 units (SEC Form 4)

    4 - TERAWULF INC. (0001083301) (Issuer)

    3/4/26 5:34:43 PM ET
    $WULF
    EDP Services
    Technology

    $APLS
    $BLUE
    $BMEA
    $BPMC
    SEC Filings

    View All

    SEC Form 6-K filed by HIVE Digital Technologies Ltd.

    6-K - HIVE Digital Technologies Ltd. (0001720424) (Filer)

    3/19/26 5:26:54 PM ET
    $HIVE
    Finance: Consumer Services
    Finance

    CDT Equity Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - CDT Equity Inc. (0001896212) (Filer)

    3/18/26 4:53:07 PM ET
    $CDT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Jet.AI Inc.

    8-K - Jet.AI Inc. (0001861622) (Filer)

    3/18/26 4:05:11 PM ET
    $JTAI
    Transportation Services
    Consumer Discretionary

    $APLS
    $BLUE
    $BMEA
    $BPMC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Telsey Advisory Group reiterated coverage on Macy's with a new price target

    Telsey Advisory Group reiterated coverage of Macy's with a rating of Market Perform and set a new price target of $20.00 from $25.00 previously

    3/19/26 7:55:45 AM ET
    $M
    Department/Specialty Retail Stores
    Consumer Discretionary

    Roth Capital initiated coverage on Apellis Pharmaceuticals with a new price target

    Roth Capital initiated coverage of Apellis Pharmaceuticals with a rating of Buy and set a new price target of $31.00

    3/13/26 8:46:55 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Cigna Group upgraded by Bernstein with a new price target

    Bernstein upgraded The Cigna Group from Mkt Perform to Outperform and set a new price target of $358.00

    3/12/26 8:38:26 AM ET
    $CI
    Medical Specialities
    Health Care

    $APLS
    $BLUE
    $BMEA
    $BPMC
    Leadership Updates

    Live Leadership Updates

    View All

    Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

    LEXINGTON, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2025. "The previous year was an important period of transition for the Company, during which we sharpened our strategic priorities," said Jasbir S. Seehra, Ph.D., President and Chief Executive

    3/4/26 4:01:00 PM ET
    $KROS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Cigna Group Announces President & COO Brian Evanko to Succeed David M. Cordani as Chief Executive Officer

    Cordani to retire as chief executive officer on July 1, 2026, and will serve as executive chair of The Cigna Group Board of DirectorsEvanko elected to the company's Board of DirectorsCompany reaffirms 2026 Financial OutlookBLOOMFIELD, Conn., March 3, 2026 /PRNewswire/ -- The Cigna Group (NYSE: CI) today announced that David M. Cordani will retire as chief executive officer effective July 1, 2026, and become executive chair of The Cigna Group's Board of Directors. Brian Evanko, current president and chief operating officer, will succeed Cordani as CEO. Throughout his tenure—inclu

    3/3/26 7:30:00 AM ET
    $CI
    Medical Specialities
    Health Care

    Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

    WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) announced today that Mikael Dolsten, M.D., Ph.D., has joined the company's board of directors as of March 1. Most recently, Dr. Dolsten served for more than 16 years as chief scientific officer and president, worldwide research, development and medical, at Pfizer, during which he presided over the regulatory approval of more than 36 medicines and vaccines.  "We are thrilled to welcome Mikael to the Apellis Board of Directors," said Cedric Francois, M.D., Ph.D., chief executive officer and co-founder, Apellis. "Mikael is a proven industry leader with deep experience developing innovative medicine

    3/2/26 7:00:00 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLS
    $BLUE
    $BMEA
    $BPMC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Gildan Activewear Inc.

    SC 13D/A - Gildan Activewear Inc. (0001061894) (Subject)

    12/4/24 4:01:46 PM ET
    $GIL
    Apparel
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Apellis Pharmaceuticals Inc.

    SC 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 4:16:13 PM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Apellis Pharmaceuticals Inc.

    SC 13G - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)

    11/22/24 8:47:59 AM ET
    $APLS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APLS
    $BLUE
    $BMEA
    $BPMC
    Financials

    Live finance-specific insights

    View All

    Macy's, Inc. and Macy's Return to Annual Comparable Sales Growth; Fourth Quarter and Fiscal Year 2025 Results Exceed Guidance

    Bold New Chapter gained traction across all nameplates during fourth quarter, driven by go-forward stores and digital Bloomingdale's achieved its best holiday performance on record in the fourth quarter Macy's expands strategic initiatives to 75 additional stores, creating "Reimagine 200" for 2026 Macy's, Inc. (NYSE:M) today reported financial results for the fourth quarter and fiscal year 2025 and provided fiscal year 2026 guidance. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260318878750/en/ Fourth Quarter 2025 Highlights Macy's, Inc. net sales of $7.6 billion exceeded guidance. Macy's, Inc. comparable sales1 gr

    3/18/26 6:55:00 AM ET
    $M
    Department/Specialty Retail Stores
    Consumer Discretionary

    Cyngn Announces Date for 2025 Fourth Quarter and Year-End Financial Results

    MOUNTAIN VIEW, Calif., March 5, 2026 /PRNewswire/ -- Cyngn (NASDAQ:CYN) will announce its 2025 fourth quarter and year-end financial results for the period ended December 31, 2025, on Wednesday, March 25, 2026, after the close of market. The financial results will be available on the Cyngn website under "News & Events" at https://investors.cyngn.com/.  The Company will not host an earnings call.About CyngnCyngn develops and deploys autonomous vehicle technology for industrial organizations like manufacturers and logistics companies. The Company addresses significant challenges f

    3/5/26 7:05:00 AM ET
    $CYN
    EDP Services
    Technology

    AM Best Affirms Credit Ratings of The Cigna Group and Its Subsidiaries

    AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of "a+" (Excellent) of the key U.S. life/health subsidiaries and Europe-based insurance companies of The Cigna Group (Cigna) (headquartered in Bloomfield, CT) (NYSE:CI). The majority of Cigna's core U.S. health insurance entities are collectively referred to as Cigna Life & Health Group. In addition, AM Best has affirmed the Long-Term ICR of "bbb+" (Good) and the Long-Term Issue Credit Ratings (Long-Term IR) of Cigna. AM Best also has affirmed the Short-Term Issue Credit Rating (Short-Term IR) of Cigna. The outlook of these Credit Ratings (ratings) is stable. (

    3/4/26 5:40:00 PM ET
    $CI
    Medical Specialities
    Health Care